SUPPLEMENT ARTICLE
Humoral and Cellular Immunity to Varicella-Zoster
Virus: An Overview
Ann M. Arvin
Department of Pediatrics, Stanford University School of Medicine, Stanford, California
INNATE IMMUNITY
Under conditions of naturally acquired primary vari-
cella-zoster virus (VZV) infection, the first response of
the naive host is mediated by the innate immune system
through antiviral cytokines and the activation of NK
cells [1]. These responses are likely to be important for
the initial control of VZV at mucosal sites of inocu-
lation and to trigger the induction and amplification
of adaptive, VZV-specific immunity. NK cells can lyse
VZV-infected targets [2], and activated NK cells are a
major source of interferon (IFN)–g production, which
enhances the clonal expansion of antigen-specific T
cells. IFN-a inhibits VZV replication in vitro, and treat-
ment with exogenous type I IFN-a reduced the severity
of varicella in immunocompromised children with var-
icella [3]. In addition, VZV replication in skin is as-
sociated with extensive production of IFN-a by adja-
cent uninfected epidermal cells in the SCIDhu model
of VZV pathogenesis; blocking this IFN-a response
caused a dramatic increase in VZV spread in skin [4].
Innate mechanisms of immune control have the ca-
pacity to maintain the host-virus equilibrium, despite
the VZV immune evasion strategies that inhibit both
class I and class II major histocompatibility complex
(MHC) mechanisms for antigen presentation to T cells
while the virus is being transferred to skin and in early
stages of cutaneous infection [4–6]. These strategies
Potential conflicts of interest: A.M.A. has received honoraria from Merck, the
manufacturer of the varicella vaccine.
Financial support: supplement sponsorship is detailed in the Acknowledgments.
Reprints or correspondence: Dr. Ann M. Arvin, G312, Dept. of Pediatrics,
Stanford University School of Medicine, 300 Pasteur Dr., Stanford, CA 94305
(aarvin@stanford.edu).
The Journal of Infectious Diseases 2008; 197:S58–60
 2008 by the Infectious Diseases Society of America. All rights reserved.
0022-1899/2008/19705S2-0006$15.00
DOI: 10.1086/522123
S58 • JID 2008:197 (Suppl 2) • Arvin
appear to be effective for delaying the acquisition of
adaptive immunity; VZV-specific T cells were not de-
Downloaded from http://jid.oxfordjournals.org/ by guest on December 11, 2016
tected during the incubation period and emerged grad-
ually after the onset of the varicella rash, appearing in
12%, 31%, and 47% of healthy subjects with varicella
who were tested at 1, 2, and 3 days after onset, re-
spectively [7, 8]. Nevertheless, the acquisition of VZV-
specific T cells appears to be necessary to prevent
disseminated infection, as suggested by the risk of life-
threatening varicella in children with malignancies or
congenital T cell immunodeficiencies or who are re-
ceiving immunosuppression for organ transplantation,
as well as to achieve resolution of the acute infection.
Children with HIV infection are at risk for chronic
varicella, which is consistent with an important role for
VZV-specific cellular immunity [9]. High frequencies
of T cells that lyse targets expressing VZV gE and im-
mediate early (IE) 62 protein are detected in healthy
subjects, but other viral proteins are also likely to be
recognized by VZV-specific T cells during acute vari-
cella [10]. The adaptive immune response to primary
VZV infection also includes the induction of B cells
that make VZV IgG and IgM antibodies, although the
magnitude of this response does not correlate with the
extent of varicella in healthy or immunodeficient chil-
dren, and B cell immunodeficiencies do not appear to
predispose to severe varicella [11, 12].
MEMORY IMMUNITY
The memory immune response that follows the reso-
lution of naturally acquired primary VZV infection is
characterized by the persistence of VZV IgG antibodies
and, in most cases, VZV IgA antibodies, as well as VZV-
specific CD4 and CD8 T cells [1]. VZV-specific IgG
antibodies have been shown to bind many VZV pro-
teins and function to mediate neutralization and an-
tibody-dependent cytotoxicity. The overall frequency of
VZV-specific memory T cells with proliferative capacity has
been estimated to be ∼1:40,000 peripheral blood mononuclear
cells [13]. These cells recognize VZV glycoproteins gE, gB, gC,
and gH and the IE62 protein [7, 14, 15], and most produce
IFN-g and tumor necrosis factor–a [16]. Among these pop-
ulations are MHC class I– or class II–restricted cytotoxic T cells
that recognize VZV proteins, including include gC, gE, gI, and
IE62 and IE63 proteins [10, 13, 17, 18]. In VZV-immune
subjects tested 120 years after varicella, the mean  SD fre-
quency of memory cytotoxic T cells specific for IE62 was 1:
105,000  85,000, and that for gE was 1: 121,000  86,000.
The function of VZV IgG antibodies in protecting the host Figure 1. Importance of the initial “burst” of the adaptive host re-
is presumed to be primarily the neutralization of infectious sponse for establishing long-term antiviral immunity. VZV, varicella-zoster
VZV at sites of inoculation on reexposure to the virus by con- virus.
tact with individuals who have varicella or herpes zoster (HZ).
Should the virus evade this first line of defense as well as the
in the naive healthy host was established in the prelicensure
local innate responses, it is likely that VZV-specific T cells are

Downloaded from http://jid.oxfordjournals.org/ by guest on December 11, 2016

important for preventing symptomatic disease after exogenous
reexposure. In addition, because VZV establishes latency in
sensory ganglia, the adaptive T cell response is needed to pre-
vent symptomatic reactivations of endogenous VZV. The com-
mon age-related decrease in VZV-specific T cells or a decrease
resulting from immunosuppressive diseases or therapies is as-
sociated with an increased risk of HZ [19]. One hypothesis is
that these exogenous and endogenous exposures to infectious
VZV may promote the maintenance of robust VZV memory
immunity, because household exposure to varicella often results
in boosts in VZV humoral and cellular immune responses, and
HZ stimulates a dramatic increase in VZV IgG antibodies and
VZV-specific T cell frequencies [20, 21]. Alternatively, the per-
sistence of memory immunity may result from the initial clonal
expansion of VZV-specific T cells with helper and effector func-
tions, without any requirement for subsequent restimulation
in the immune host.
VACCINE IMMUNITY
According to current models, memory antiviral immunity is
thought to be a consequence of the magnitude of the expansion
of effector cell populations elicited by primary exposure to the
pathogen [22] (figure 1). Memory immune responses are lower
when the initial immunologic “burst” is limited, because virus-
specific effector cell populations are normally regulated to de-
crease during the weeks to months after primary sensitization
and expansion. The antigenic signal appears to be the most
important factor in driving the expansion and, therefore, is
expected to have direct consequences for the immunologic “set
point” of the memory immune response. VZV immune re-
sponses peak within a few weeks after naturally acquired in-
fection and decline to a persistent memory response with the
characteristics described earlier. The capacity of the live atten-
uated varicella vaccine to elicit VZV IgG and T cell immunity
clinical evaluations of the vaccine [23]. As expected, the mag-
nitude of these VZV-specific immune responses was related to
the infectious virus content and to the antigen content of the
vaccine preparation [24, 25]. Host factors also play a role, in
that achieving responses in naive adolescents and adults that
were equivalent to those of younger children required the ad-
ministration of 2 doses of varicella vaccine. However, providing
2 doses to younger children resulted in higher VZV IgG an-
tibody titers and T cell proliferation responses, and some evi-
dence, as reviewed by Watson [26] in this supplement, suggests
that memory responses were sustained more effectively. This
information has led to the recent recommendation to imple-
ment a 2-dose regimen of varicella vaccine in all age groups
[27]. Because varicella epidemics have occurred annually in
temperate climates and primary VZV infection appears to result
invariably in the establishment of latent infection, with the
potential for causing subclinical reactivation, it has not been
possible to determine the relative importance of the primary
host response and subsequent boosting for preserving protec-
tive immunity against VZV. By comparison with other live
attenuated vaccines, such as measles vaccine, repeated exoge-
nous or endogenous contact with wild-type VZV will probably
not be required to maintain persistent immunity. However, the
continuation of active and passive surveillance programs to
monitor VZV infections in all age groups, as described in this
supplement, will make it possible to determine whether ad-
ditional booster doses of varicella vaccine should be given.
Acknowledgments
Supplement sponsorship. This article was published as part of a sup-
plement entitled “Varicella Vaccine in the United States: A Decade of Pre-
vention and the Way Forward,” sponsored by the Research Foundation for
Microbial Diseases of Osaka University, GlaxoSmithKline Biologicals, the
Sabin Vaccine Institute, the Centers for Disease Control and Prevention,
and the March of Dimes.

Humoral and Cellular Immunity to VZV • JID 2008:197 (Suppl 2) • S59

References
1. Arvin AM. Varicella-zoster virus. In: Knipe DM, Howley P, eds. Fields’
virology, 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:
2731–68.
2. Ihara T, Kato T, Torigoe S, et al. Antibody response determined with
antibody-dependent cell-mediated cytotoxicity (ADCC), neutralizing
antibody, and varicella skin test in children with natural varicella and
after varicella immunization. Acta Paediatr Jpn 1991; 33:43–9.
3. Arvin AM, Kushner JH, Feldman S, et al. Human leukocyte interferon
for treatment of varicella in children with cancer. N Engl J Med
1982; 306:761–7.
4. Ku C-C, Zerboni L, Besser J, Ito H, Arvin AM. Varicella-zoster virus
transfer to skin by T cells and modulation of viral replication by epi-
dermal cell interferon-a. J Exp Med 2004; 200:917–25.
5. Abendroth A, Slobedman B, Eunice L, Mellins E, Wallace M, Arvin
AM. Modulation of MHC class II protein expression by varicella zoster
virus. J Virol 2000; 74:1900–7.
6. Abendroth A, Lin I, Slobedman B, Ploegh H, Arvin AM. Varicella-
zoster virus retains major histocompatibility complex class I proteins
in the Golgi compartment of infected cells. J Virol 2001; 75:4878–88.
7. Arvin AM, Koropchak CM, Williams BR, Grumet FC, Foung SK. Early
immune response in healthy and immunocompromised subjects with
primary varicella-zoster virus infection. J Infect Dis 1986; 154:422–9.
8. Arvin A. Varicella-zoster virus: virologic and immunologic aspects of
persistent infection. In: Ahmed R, Chen I, eds. Persistent viral infec-
tions. New York: John Wiley & Sons, 1998:183–208.
9. Gershon AA, Mervish N, LaRussa P, et al. Varicella-zoster virus infec-
tion in children with underlying human immunodeficiency virus in-
fection. J Infect Dis 1997; 176:1496–500.
10. Diaz PS, Smith S, Hunter E, Arvin AM. T lymphocyte cytotoxicity
with natural varicella-zoster virus infection and after immunization
with live attenuated varicella vaccine. J Immun 1989; 142:636–41.
11. Arvin AM, Sharp M, Smith S, et al. Equivalent recognition of a var-
icella-zoster virus immediate early protein (IE62) and glycoprotein I
by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype. J
Immunol 1991; 146:257–64.
12. Webster AD, Spickett GP, Thomson BJ, Farrant J. Viruses and antibody
deficiency syndromes. Immunol Invest 1988; 17:93–105.
13. Hayward AR, Pontesilli O, Herberger M, Laszlo M, Levin M. Specific
lysis of varicella zoster virus-infected B lymphoblasts by human T cells.
J Virol 1986; 58:179–84.
14. Jenkins DE, Redman RL, Lam EM, Liu C, Lin I, Arvin AM. Interleukin
S60 • JID 2008:197 (Suppl 2) • Arvin
(IL)-10, IL-12, and interferon-g production in primary and memory
immune responses to varicella-zoster virus. J Infect Dis 1998; 178:
940–8.
15. Huang Z, Vafai A, Lee J, Mahalingam R, Hayward AR. Specific lysis
of targets expressing varicella-zoster virus gpI or gpIV by CD4+ human
T-cell clones. J Virol 1992; 66:2664–9.
16. Asanuma H, Sharp M, Maecker HT, et al. Frequencies of memory T
cells specific for varicella-zoster virus, herpes simplex virus and cy-
tomegalovirus determined by intracellular detection of cytokine ex-
pression. J Infect Dis 2000; 181:859–66.
17. Sharp M, Terada K, Wilson A, et al. Kinetics and viral protein specificity
of the cytotoxic T lymphocyte response in healthy adults immunized
with live attenuated varicella vaccine. J Infect Dis 1992; 165:852–8.
18. Sadzot-Delvaux C, Kinchington P, Rentier B, Arvin AM. Recognition
of the latency-associated immediate early protein IE63 of varicella-
zoster virus by human memory T lymphocytes. J Immunol 1997; 159:
2802–6.
19. Levin MJ, Smith JG, Kaufhold RM, et al. Decline in varicella-zoster
virus (VZV)–specific cell-mediated immunity with increasing age and
boosting with a high-dose VZV vaccine. J Infect Dis 2003; 188:1336–44.
20. Arvin AM, Koropchak CM, Wittek AE. Immunologic evidence for re-
Downloaded from http://jid.oxfordjournals.org/ by guest on December 11, 2016
infection with varicella-zoster virus. J Infect Dis 1983; 148:200–5.
21. Gershon AA, Steinberg SP, Gelb L. Clinical reinfection with varicella-
zoster virus. J Infect Dis 1984; 149:137–42.
22. Gourley TS, Wherry EJ, Masopust D, Ahmed R. Generation and main-
tenance of immunological memory. Semin Immunol 2004; 16:323–33.
23. Gershon AA, LaRussa P, Hardy I, Steinberg S, Silverstein S. Varicella
vaccine: the American experience. J Infect Dis 1992; 166(Suppl 1):
S63–8.
24. Bergen RE, Diaz PS, Arvin AM. The immunogenicity of the Oka/Merck
varicella vaccine in relation to infectious varicella-zoster virus and rel-
ative viral antigen content. J Infect Dis 1990; 162:1049–54.
25. Watson B, Piercy S, Soppas D, et al. The effect of decreasing amounts
of live virus, while antigen content remains constant, on immunoge-
nicity of Oka/Merck varicella vaccine. J Infect Dis 1993; 168:1356–60.
26. Watson B. Humoral and cell-mediated immune responses in children
and adults after 1 and 2 doses of varicella vaccine. J Infect Dis 2008;
197(Suppl 2):S143–6 (in this supplement).
27. Advisory Committee on Immunization Practices, Centers for Disease
Control and Prevention. Recommendations of the ACIP on varicella
immunization. Available at: http://www.cdc.gov/vaccines/recs/acip/de
fault.htm. Accessed 16 November 2007.